724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

    August 2024 in “ British Journal of Dermatology ”
    David Rosmarin, Neil S. Sadick, Timothy Rodgers, Edward Lain, Lawrence Osman, Stephen M. Schleicher, Adam Reich, Jacek C Szepietowski, Agnieszka Owczarczyk‐Saczonek, Wojciech Baran, Bartłomiej Kwiek, Michal Torz, Jacek Zdybski, Sohail S. Chaudhry, Zachary Lee, Heng Xu, Yi Liu, Brian Lewis, Katie Mellskog, Lucinda M Elko-Simms, Christie Fanton, Mary Tagliaferri, Jonathan Zalevsky, Charles Lynde
    TLDR Rezpegaldesleukin shows promise for treating severe alopecia areata.
    This phase 2b study is investigating the efficacy and safety of rezpegaldesleukin (REZPEG), a novel biologic therapy, in treating severe to very severe alopecia areata (AA). REZPEG is designed to selectively expand regulatory T cells, potentially offering a new therapeutic approach for AA, a condition with no currently approved biologic treatments. The study involves JAK-inhibitor naïve patients, with participants randomly assigned to different dosing regimens of REZPEG or placebo. The primary endpoint is the percent change in the Severity Alopecia Tool (SALT) score from baseline. The trial is ongoing, and REZPEG shows promise for providing prolonged therapeutic benefits for chronic inflammatory skin conditions like AA and atopic dermatitis.
    Discuss this study in the Community →